BioLargo at Sustain SoCal's Water Solutions 8

BioLargo was honored to be a platinum sponsor of last week's Sustain SoCal Water Solutions 8 conference, focused on innovation and innovators in the water space in Southern California. There were fascinating talks by key local groups including the Moulton Niguel Water District and Metropolitan Water District of Southern California.

Our own presentation at the event focused on BioLargo's solutions for removing and destroying per- and polyfluoroalkyl substances (PFAS) that contaminates groundwater and drinking water around the state and across the country. Our Aqueous Electrostatic Concentrator (AEC) system can meet or beat the EPA's proposed new drinking water standards, while creating a tiny fraction of the amount of PFAS-contaminated solid waste compared to carbon-based capture systems. Then, we handle the customer's waste, cradle-to-grave.

So many interesting presentations at this year's events, including by SkyH2O's Alexander von Welczeck, whose company's "SkyH2O stations" can provide clean, safe drinking water anywhere by pulling it out of the atmosphere.

Also of note - a very interesting talk about battery energy storage systems (BESS) being deployed at wastewater treatment operations to ensure constant operation even in the face of fluctuating or interrupted electrical supply from the grid. 

A special thanks to Sustain SoCal's Scott Kitcher, who not only put on another highly successful innovation-centric water event, but also heads such an amazing industry group that catalyzes partnership and collaboration to further our shared goal of making OC a hub for water innovation.

BioLargo’s YTD Revenues Up 127% Compared to Last Year Period

Following extraordinary Q1, quarter-over-quarter sales were down as company supported inventory build-up for national retailers; six month revenue ($5.2 million) was 88% of last year’s total revenue ($5.9 million)

Westminster, CA – August 15, 2023 – BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, yesterday filed its Quarterly Report (www.biolargo.com/sec-filings). Company management below provides a summary of the report’s highlights.

BioLargo will hold an investor webcast on Wednesday, August 16, 2023, at 3:00 pm Pacific / 6:00 pm Eastern, at the following link, open to the public: https://www.webcaster4.com/Webcast/Page/2448/48925

Dennis P. Calvert, BioLargo’s President and CEO, said, “2023 is shaping up to be a great year. We are especially excited as the Pooph team continues its national advertising campaign and successfully adds more retailers to carry the product. They aim to secure contracts for more than 20,000 retail stores to carry the product and those efforts are underway.  We have witnessed first-hand how the team at Pooph executes with precision and will continue to support these ambitious goals.”

Financial highlights from the quarterly report are as follows – all interested parties are encouraged to review the full quarterly report filed with the SEC to get the most complete information about BioLargo and its growing cleantech business.

• Consolidated revenues for the three months ended June 30, 2023, were $1,446,000, a 9% increase over the same period in 2022, and a 61% decrease over the three months ended March 31, 2023.
• The company’s revenues through June 30, 2023 were $5,188,000, a 127% increase over the same period of 2022.
• Net loss for the three months ended June 30, 2023, was $1,626,000, compared to $1,333,000 in the same period in 2022, and $425,000 for the three months ended March 31, 2023.
• Net stockholders’ equity at June 30, 2023, rose to $4,120,000 from $3,550,000 at March 31, 2023.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo Q2 2023 Earnings Results Webcast and Conference Call on Wednesday, August 16, 2023 - 6:00 PM Eastern Time

Westminster, CA – August 11, 2023 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced it will host an investor webcast and conference call on Wednesday, August 16th, 2023, at 3:00 pm Pacific / 6:00 pm Eastern. The event, which will be open to the public, will be held to review the company’s financial results for the three months ended June 30th, 2023, discuss recent milestones, and conduct a question-and-answer session.

To listen to a live broadcast, go to the site linked below at least 15 minutes prior to the scheduled start time to register and download any necessary audio/video software.

To participate in the live webcast and teleconference:

Webcast Link: https://www.webcaster4.com/Webcast/Page/2448/48925

Teleconference Domestic: 888-506-0062

Teleconference International: 973-528-0011

Participant Access Code: 590380

To watch or listen to a replay of the webcast or teleconference:

Webcast Replay Expiration: Friday, November 17, 2023

Teleconference Replay Expiration: Thursday, August 30, 2023

Teleconference Replay Domestic: 877-481-4010

Teleconference Replay International: 919-882-2331

Replay Passcode:  48925

The webcast replay and accompanying presentation materials will be made available on the Investor Relations section of BioLargo’s website at www.biolargo.com/investor-relations. 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.   

Contact Information

Dennis P. Calvert 

President and CEO, BioLargo, Inc. 

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Sequire Spotlight Presents BioLargo (BLGO): Sustainable Solutions to Make Life Better

 Source: Sequire Spotlight

Host Jonathan Miller interviews CEO: Dennis P. Calvert. He provides information about their technologies removing harmful airborne contaminants, including volatile organic compounds, odors, and pathogens.

BioLargo – Innovative CleanTech Company Combating "Forever Chemicals" Talks Impressive Q1 Numbers

 Source: Johnny Rice, Benzinga Staff Writer (https://www.benzinga.com/tech/23/06/33021698/biolargo-innovative-cleantech-company-combating-forever-chemicals-talks-impressive-q1-numbers) 

Dennis Calvert, President & CEO of BioLargo, Inc (OTCQB:BLGO) was recently a guest on Benzinga’s All-Access.

BioLargo is a cleantech and life sciences innovator and engineering services solution provider. Its core products address Per- and Polyfluorinated Substances (PFAS) contamination, achieve advanced water and wastewater treatment, control odor and Volatile Organic Compounds (VOCs), improve air quality and control infections and infectious disease.

The company just announced its financials for the first quarter of 2023. Mr. Calvert spoke regarding the positive numbers which included a near 300% growth in revenue for the quarter year-over-year.

Watch the full interview here:

BioLargo, Inc. Discusses Record-Breaking Financial Results, Innovation-Pipeline Business Model, and More with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - June 5, 2023) - The Stock Day Podcast welcomed BioLargo, Inc. (OTCQB: BLGO), a cleantech and life sciences innovator and engineering services solution provider. President and CEO of BioLargo, Inc., Dennis P. Calvert, joined Stock Day host Kevin Davis.

The interview covered the following topics:

• The company's first quarter financial results, including increased revenues from sales of private-label pet odor product Pooph (www.pooph.com),
• Progress at the company's engineering group,
• Progress at subsidiary Clyra Medical and its Bioclynse surgical wound irrigation solution,
• The company's overall innovation development cycle; and
• The company's sodium-sulfur battery technology.

"What we're going to witness, we believe, is exactly what's happening at Pooph has the potential to happen for all the other operating assets in the portfolio," said Mr. Calvert. "In each case, we've done the hardest work to invent, prove up, find first commercial adoption, and then find distribution through partnerships."

To hear Dennis Calvert's entire interview, follow the link to the podcast here: https://audioboom.com/posts/8312041-biolargo-inc-discusses-record-breaking-financial-results-innovation-pipeline-business-model-a.

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/.

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.

SOURCE:
Stock Day Media
(602) 821-1102

About BioLargo, Inc.

BioLargo, Inc. (OTCQB: BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Its core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, and control infections and infectious disease. Its business approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. www.BioLargo.com

Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as "we believe". These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo Announces 288% Revenue Growth in Quarterly Report

Company’s revenues grew 288% compared to the same period last year, and grew 78% compared to the fourth quarter of 2022. The company’s net loss dropped by 68% from the same period last year.

Westminster, CA – May 17, 2023 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, yesterday filed its Quarterly Report for the three months ended March 31, 2023 (www.biolargo.com/sec-filings). Company management below provides a summary of the quarterly report’s highlights.

BioLargo will hold an investor webcast on Thursday, May 18, 2023, at 1:30 pm Pacific / 4:30 pm Eastern, at the following link, open to the public: https://www.webcaster4.com/Webcast/Page/2448/48436

Dennis P. Calvert, the company’s President and CEO, said, “We’re confident that the long-term success of our pet odor control product partnership – Pooph – bolstered by the rollout of key water treatment technologies, will drive our company to our goal of profitability and beyond.”

Company management provides highlights of the quarterly report below, but encourages investors to review the full report to get the most complete information about BioLargo and its growing cleantech business.

Highlights:

• Consolidated revenue for the three months ended March 31, 2023, was $3,742,000, which was a 288% increase over the same period in 2022, and a 78% increase over the previous quarter (Q4 of 2022).
• The company’s net loss was reduced by 68% compared to the same period in 2022, to $494,000.
• Net stockholders’ equity rose to $3,552,000 from $2,011,000 in the fourth quarter of 2022.
• The company ended the quarter with $3,264,000 in cash, compared to $1,851,000 at December 31, 2022.
• A standout performer in BioLargo’s portfolio was ONM Environmental, the company’s odor and VOC control subsidiary, whose revenues grew 491% compared to the same period of 2022, to $3,543,000. ONM Environmental’s operating income also grew 10,569% from the same period of 2022, to $1,387,000. The subsidiary’s significant growth in revenue is largely attributed to the growing success of the pet odor control product Pooph, sold by the company’s partners at Ikigai Marketing Works, LLC, which comprised 90% of its revenues (and 86% of BioLargo company-wide revenues).
• Revenues at BioLargo Engineering, Science & Technologies, LLC decreased by 45% to $193,000, as compared to the same period in 2022, and its operating loss increased to $368,000, as compared to $35,000 in the same period in 2022.

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding tanticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.